← Eichor
Study identifier: NCT07647094 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer

Condition: NSCLC  ·  Sponsor: People's Hospital of Quzhou

PhaseEARLY_Phase 1
Planned participants112
Who can joinAll sexes, 18 Years to 75 Years
Healthy volunteersNo

About this study

This study is a multicenter randomized controlled clinical trial targeting subjects with advanced or metastatic squamous NSCLC with unknown or negative gene status, aiming to evaluate the efficacy and safety of first-line delayed administration of Serplulimab combined with a low-dose Nab-Paclitaxel doublet chemotherapy regimen.

This description comes directly from the study's public registry record.

Talk to the study team

Xuru Jin  ·  13857782369  ·  wzjxr@qq.com

Always discuss trial participation with your own doctor first.

Locations (1)

Quzhou people's HospitalQuzhou, Zhejiang, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07647094